Abstract
Venous thromboembolism (VTE), major adverse cardiovascular events (MACE), neoplasia, and serious infections are significant complications associated with Immune-mediated inflammatory diseases. Actually, the occurrence of such complications in these patients has been observed to be higher than that anticipated from classical risk factors alone. Additionally, the administration of anti-inflammatory treatments, such as corticosteroids, associated to inflammatory diseases is recognized to further elevate this risk. In Spain, data on the prevalence of risk of cardiovascular events, neoplasia or serious infections, particularly among individuals with ulcerative colitis are scarce. This study leverages real-world data from the Andalusian Health Population Database (BPS) to analyze the incidence and risk factors of these complications among ulcerative colitis patients. A cohort of 23,518 patients, aged 18 years or older, with an ulcerative colitis diagnosis between 2010 and 2019, was used in the study. The objective was to assess the incidence of VTE, MACE, neoplasms, and serious infections and to evaluate the impact of age and other factors related to ulcerative colitis on these outcomes.
The study revealed a notably higher incidence of VTE and MACE in ulcerative colitis patients compared to the incidence described for the general population, particularly among those over 60 years of age. Specifically, the incidence of VTE was significantly elevated post-diagnosis, with deep vein thrombosis (DVT) and pulmonary embolism, being the most common manifestations. MACE, including myocardial infarction and stroke, also presented a higher risk, especially in older patients. Also, a significant portion of patients developed various malignancies. Also remarkable is the significant higher incidence of VTE, malignancies and serious infections as the severity of ulcerative colitis increases. The use of immunosuppressive therapies was associated with an increased risk of infections, and likely with VTE and malignancies, further complicating the management of these patients.
The findings of this study underscore the need for heightened vigilance in the management of ulcerative colitis patients, particularly those at advanced ages. Preventive strategies, such as thromboprophylaxis during hospitalization and regular monitoring for cardiovascular and neoplastic complications, are essential. The study contributes valuable insights into the burden of comorbidities in ulcerative colitis and highlights the importance of tailored treatment and monitoring strategies to improve patient outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work has been funded by Pfizer quality improvement project entitled "Real world data analysis of venous thromboembolism, major adverse cardiovascular events, neoplasia and severe infections in the Andalusian Population Health Database for the improvement of the management of patients with ulcerous colitis and atopic dermatitis" (77644553) and co-financed by the Consejeria de Salud y Consumo, Junta de Andalucia (IE19_259 FPS).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Andalusian Biomedical Research Ethics Coordinating Committee approved the study entitled: "Analysis of real-world data on venous thromboembolism, major adverse cardiovascular events, neoplasms and serious infections in the Andalusian Population Health Database to improve the management of patients with ulcerative colitis and atopic dermatitis" (March 28, 2023, Acta 03/23) and waived informed consent for the secondary use of clinical data for research purposes.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos